537 related articles for article (PubMed ID: 25658389)
1. Hepatitis C therapy: Looking toward interferon-sparing regimens.
Au TH; Destache CJ; Vivekanandan R
J Am Pharm Assoc (2003); 2015; 55(2):e72-84; quiz e85-6. PubMed ID: 25658389
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists.
Deming P; Martin MT; Chan J; Dilworth TJ; El-Lababidi R; Love BL; Mohammad RA; Nguyen A; Spooner LM; Wortman SB
Pharmacotherapy; 2016 Feb; 36(2):203-17. PubMed ID: 26846728
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
4. Future perspectives: towards interferon-free regimens for HCV.
Gane E
Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens.
Vespasiani-Gentilucci U; Galati G; Gallo P; De Vincentis A; Riva E; Picardi A
World J Gastroenterol; 2015 Jun; 21(24):7412-26. PubMed ID: 26139987
[TBL] [Abstract][Full Text] [Related]
6. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
[TBL] [Abstract][Full Text] [Related]
7. The role of interferon in the new era of hepatitis C treatments.
Parekh PJ; Shiffman ML
Expert Rev Gastroenterol Hepatol; 2014 Aug; 8(6):649-56. PubMed ID: 24758387
[TBL] [Abstract][Full Text] [Related]
8. Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting.
Höner Zu Siederdissen C; Maasoumy B; Deterding K; Port K; Sollik L; Mix C; Kirschner J; Cornberg J; Manns MP; Wedemeyer H; Cornberg M
Liver Int; 2015 Jul; 35(7):1845-52. PubMed ID: 25556625
[TBL] [Abstract][Full Text] [Related]
9. New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development.
Pawlotsky JM
Semin Liver Dis; 2014 Feb; 34(1):22-9. PubMed ID: 24782255
[TBL] [Abstract][Full Text] [Related]
10. [Chronic hepatitis C infection--eradication of the virus].
Ben Ari Z
Harefuah; 2014 Jul; 153(7):392-3, 433. PubMed ID: 25189028
[TBL] [Abstract][Full Text] [Related]
11. Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now.
Florian J; Mishra P; Arya V; Harrington P; Connelly S; Reynolds KS; Sinha V
Clin Pharmacol Ther; 2015 Oct; 98(4):394-402. PubMed ID: 26179495
[TBL] [Abstract][Full Text] [Related]
12. Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.
Childs-Kean LM; Hand EO
Clin Ther; 2015 Feb; 37(2):243-67. PubMed ID: 25601269
[TBL] [Abstract][Full Text] [Related]
13. Current therapies for chronic hepatitis C.
Ferguson MC
Pharmacotherapy; 2011 Jan; 31(1):92-111. PubMed ID: 21182362
[TBL] [Abstract][Full Text] [Related]
14. Chronic hepatitis C virus management: 2000-2005 update.
Hughes CA; Shafran SD
Ann Pharmacother; 2006 Jan; 40(1):74-82. PubMed ID: 16368925
[TBL] [Abstract][Full Text] [Related]
15. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus: standard-of-care treatment.
Pawlotsky JM
Adv Pharmacol; 2013; 67():169-215. PubMed ID: 23886001
[TBL] [Abstract][Full Text] [Related]
17. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
[TBL] [Abstract][Full Text] [Related]
18. The rapid evolution of treatment strategies for hepatitis C.
Muir AJ
Am J Gastroenterol; 2014 May; 109(5):628-35; quiz 636. PubMed ID: 24732866
[TBL] [Abstract][Full Text] [Related]
19. Ledipasvir + sofosbuvir (Harvoni). A therapeutic advance in genotype 1 hepatitis C virus infection, despite uncertainties.
Prescrire Int; 2015 Dec; 24(166):285-9. PubMed ID: 26788571
[TBL] [Abstract][Full Text] [Related]
20. Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient.
Chute DF; Chung RT; Sise ME
Kidney Int; 2018 Mar; 93(3):560-567. PubMed ID: 29325996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
